Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analysts following Alterity Therapeutics know that every SEC release can shift the outlook for ATH434’s Parkinsonian trials. Whether you need the latest Alterity Therapeutics quarterly earnings report 10-Q filing to gauge cash runway, or want to monitor Alterity Therapeutics insider trading Form 4 transactions before pivotal data, this page covers the entire journey.
Stock Titan’s AI instantly converts dense 10-Ks into concise, plain-English overviews—perfect when you’re understanding Alterity Therapeutics SEC documents with AI instead of wading through scientific jargon. Set real-time alerts for Alterity Therapeutics Form 4 insider transactions, scan 8-K material events explained for fresh clinical results, or dive into the proxy statement executive compensation tables without scrolling hundreds of pages.
Each filing type answers a different biotech question: 10-Qs reveal R&D burn and trial milestones; 10-Ks provide a lab-to-market road map in one place—an Alterity Therapeutics annual report 10-K simplified. Curious about board decisions? The Alterity Therapeutics proxy statement executive compensation breaks down incentives tied to ATH434 progress. Want color on collaborations or sudden capital raises? An Alterity Therapeutics 8-K material events explained section flags them the moment they hit EDGAR. All documents are indexed, searchable, and paired with AI-powered summaries so you can compare quarter-over-quarter results, track Alterity Therapeutics earnings report filing analysis, and spot Alterity Therapeutics executive stock transactions Form 4 patterns—faster than ever. Make smarter biotech decisions with complete, real-time coverage designed for professionals who can’t afford to miss a single disclosure.
On 06/30/2025, Arvinas, Inc. (ARVN) filed a Form 4 disclosing equity awards granted to director Sunil Agarwal on 06/25/2025. The filing reports two separate awards:
- 16,025 Restricted Stock Units (RSUs) acquired at no cost. Each RSU converts into one common share once vested. Vesting occurs in full on the earlier of 25 Jun 2026 or the first board meeting following the next annual shareholder meeting, contingent on the director’s continued service.
- 23,105 stock options carrying a $7.80 exercise price and expiring 24 Jun 2035. These options follow the same one-year cliff vesting schedule as the RSUs.
No shares were sold or disposed of in this transaction. Following the grant, Agarwal’s direct beneficial ownership stands at 30,166 common shares, in addition to the newly issued 23,105 options.
The transaction was coded “A” (acquisition) and carried out for no cash consideration, indicating a routine director compensation grant rather than open-market activity.
Alterity Therapeutics has submitted a Form 6-K to announce an upcoming corporate update regarding ATH434, their key therapeutic candidate. The filing indicates that CEO Geoffrey P. Kempler will provide details about the company's progress through Exhibit 99.1.
Key points from this filing include:
- Filed as a foreign private issuer under Rule 13a-16/15d-16
- Company files annual reports under Form 20-F
- Filing will be incorporated into multiple registration statements including Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076)
- Document signed by Geoffrey P. Kempler in his capacity as Chairman
This filing suggests potential material developments regarding ATH434, which could be significant for investors following Alterity's drug development pipeline. The corporate update may include clinical progress, regulatory developments, or other strategic initiatives related to their therapeutic program.
FAQ
What is the current stock price of Alterity Therapeutics (ATHE)?
What is the market cap of Alterity Therapeutics (ATHE)?
What is Alterity Therapeutics Ltd?
Which therapeutic areas does the company focus on?
What are the main drug candidates developed by Alterity Therapeutics?
How does Alterity Therapeutics generate revenue?
How is the company positioned within the competitive biotechnology landscape?
What makes ATH434 significant in the treatment of Parkinson's disease?
Has the company undergone any significant changes recently?
What collaborative efforts support Alterity Therapeutics' clinical research?
